Program
MICC 2020 Program
Print Full programTime | Session/Lecture info |
---|---|
09:00-09:30 | Registration & Coffee
|
09:30-09:50 | Opening: Varda Rotter, Chair of Organizing Committee
Greeting: Alon Chen, President, The Weizmann Institute of Science Mandy Moross, introduced by Moshe Oren, Director, Moross Integrated Cancer Center |
09:50-12:00 | Session 1
Chairs: Ayelet Erez and Neta Erez |
09:50-10:15 |
Eyal Gottlieb, Technion Israel Institute of Technology
Revealing and targeting metabolic vulnerabilities of cancer
|
10:15-10:40 |
Ayelet Erez, Weizmann Institute of Science
Modulating amino acid cross- talks between the tumor and the host to improve cancer diagnosis and therapy
|
10:40-11:05 |
Yardena Samuels, Weizmann Institute of Science
Deciphering the highly complex melanoma HLA-presented landscape
|
11:05-11:30 |
Neta Erez, Tel Aviv University
Inflammatory crosstalk between stromal and immune cells shapes the metastatic microenvironment
|
11:30-11:45 |
Ido Yofe, Weizmann Institute of Science
Spatial and temporal mapping of immune cells dynamics in breast cancer metastasis
|
11:45-12:00 |
Noa Furth, Weizmann Institute of Science
The Combinatorial Epigenome of H3-K27M Pediatric Gliomas in Single-Molecule Resolution
|
12:00-13:30 | Lunch and poster session
|
13:30-15:00 | Session 2
Chairs: Naama Geva-Zatorsky and Ravid Straussman |
13:30-13:55 |
Gideon Rechavi, The Chaim Sheba Medical Center
Epitranscriptomics: From basic research to cancer therapy
|
13:55-14:20 |
Naama Geva-Zatorsky, Technion Israel Institute of Technology
Plasticity in microbiome-host interactions
|
14:20-14:45 |
Sima Lev, Weizmann Institute of Science
Therapeutic approaches targeting Triple-Negative Breast Cancer heterogeneity
|
14:45-15:00 |
Anabel Eckerling, Tel Aviv University
Dormancy and progression of metastases: Effects of primary tumor secretome and surgery
|
15:00-15:25 | Coffee Break
|
15:25-17:05 | Session 3
Chairs: Varda Rotter and Itay Tirosh |
15:25-15:50 |
Itay Tirosh, Weizmann Institute of Science
Intra-tumor heterogeneity in head and neck cancer
|
15:50-16:15 |
Varda Rotter, Weizmann Institute of Science
Can mutant p53 change faces
into guardian of the genome?
|
16:15-16:40 |
Ziv Shulman, Weizmann Institute of Science
Antibody-mediated immune responses against tumors in ovarian cancer patients
|
16:40-17:05 |
George Miller via Zoom, Trinity Health of New England
The Hepatic Microbiome Governs Liver Immunity
|
17:05-17:30 | Coffee Break
|
17:30-18:20 | Session 4
Chair: Valery Krizhanovsky |
17:30-17:55 |
Tom Gajewski via Zoom, The University of Chicago
Microbiome and germline variants can regulate anti-tumor immunity through myeloid cells
|
17:55-18:20 |
Jennifer Wargo via Zoom, MD Anderson Cancer Center
Targeting the microbiome to treat, intercept, and prevent cancer
|
18:20-19:05 | Session 5
Chairs: Moshe Oren |
18:20-19:05 |
Keynote lecture John Dick via Zoom, University of Toronto
A cellular hierarchy framework for understanding heterogeneity and predicting drug response in human B-ALL and AML
|
Organizing committee
Varda Rotter, chair
Weizmann Institute of Science
Ari Elson, co-chair
Weizmann Institute of Science
Eyal Gottlieb
Technion-Israel Institute of Technology
Valery Krizhanovsky
Weizmann Institute of Science
Ruth Scherz-Shouval
Weizmann Institute of Science
Avi Schroeder
Technion-Israel Institute of Technology
Yuval Shaked
Technion-Israel Institute of Technology
Sponsors
The Chorafas Institute for Scientific Exchange
Administrative Organizer
Dina Preise
Conference Coordinator & Accessibility issues
Talia Suissa